Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

EMANATE: Studie setmelanotidu u pacientů se specifickými genovými variantami v dráze MC4R

19. října 2026 aktualizováno: Rhythm Pharmaceuticals, Inc.

Randomizovaná, dvojitě zaslepená, placebem kontrolovaná studie fáze 3: Vícenásobné nezávislé dílčí studie setmelanotidu u pacientů s genovými variantami POMC/PCSK1, LEPR, NCOA1(SRC1) nebo SH2B1 v dráze receptoru melanokortinu-4

The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in participants with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway:

  • Pro-opiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1; Sub-study 035a)
  • Leptin receptor (LEPR; Sub-study 035b)
  • Nuclear receptor coactivator 1 (NCOA1; steroid receptor coactivator 1 [SCR1]; Sub-study 035c)
  • Steroid receptor coactivator-1 homology 2 B adapter protein 1 (SH2B1; Sub-study 035d)

The objectives and endpoints are identical for these sub-studies.

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Aktuální)

296

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Lyon, Francie, 69677
        • GH Est Hopital Femme Mere Enfant
      • Paris, Francie, 75651
        • Hu Pitie Salpetriere Aphp
      • Paris, Francie, 75771
        • Hopital Armand Trousseau
      • Pessac, Francie, 33604
        • Centre Hospitalier Universitaire (CHU) de Bordeaux
      • Saint-Denis, Francie, 97400
        • Hôpital Félix Guyon Bellepierre
      • Toulouse, Francie
        • CHU de Toulouse Hopital des Enfants
      • Rotterdam, Holandsko, 3015 GD
        • Erasmus Medisch Centrum
      • Petah Tikva, Izrael, 49372
        • Hasharon Hospital
      • Ramat Gan, Izrael, 52621
        • Chaim Sheba MC, Safra Children's Hospital
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2E1
        • University of Alberta - Alberta Diabetes Institute (ADI)
    • Ontario
      • Toronto, Ontario, Kanada, M5G 1X8
        • The Hospital for Sick Children
      • Berlin, Německo, 10117
        • Charite - Universitatsmedizin Berlin
      • Frankfurt, Německo, 60596
        • Endokrinologikum Frankfurt
      • Leipzig, Německo, 04103
        • Universitaetsklinikum Leipzig
      • Ulm, Německo, 89075
        • Universitaetsklinikum Ulm
      • San Juan, Portoriko, 00925-253
        • University of Puerto Rico
      • San Juan, Portoriko, 00927
        • Puerto Rico Consortium for Clinical Investigation, Inc.
      • Bristol, Spojené království, BS2 8AE
        • Bristol Royal Hospital for Children
      • Cambridge, Spojené království, CB2 0QQ
        • University of Cambridge
      • Liverpool, Spojené království, L9 7AL
        • Aintree University Hospital
      • London, Spojené království, W2 1NY
        • Imperial College Healthcare Trust
      • London, Spojené království, NW1 2PG
        • London Medical - The London Diabetes Centre
      • London, Spojené království, WC1E6JF
        • University College London Hospitals NHS Foundation Trust
      • Manchester, Spojené království, M13 9WL
        • Manchester Children's Hospital
    • Arizona
      • Phoenix, Arizona, Spojené státy, 85016
        • Phoenix Children's Hospital
      • Scottsdale, Arizona, Spojené státy, 85258
        • HonorHealth Bariatric Center
    • California
      • Los Angeles, California, Spojené státy, 90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora, Colorado, Spojené státy, 80045
        • Children's Hospital Colorado
    • Connecticut
      • New Haven, Connecticut, Spojené státy, 06519
        • Yale Center for Clinical Investigation
    • Florida
      • Altamonte Springs, Florida, Spojené státy, 32701
        • Advent Health
      • Gainesville, Florida, Spojené státy, 32610
        • University of Florida
    • Georgia
      • Suwanee, Georgia, Spojené státy, 30024
        • InQuest Medical Research
    • Massachusetts
      • Worcester, Massachusetts, Spojené státy, 01655
        • UMASS Memorial Medical Center
    • Michigan
      • Ann Arbor, Michigan, Spojené státy, 48105
        • University of Michigan
      • Dearborn, Michigan, Spojené státy, 48126-2619
        • Metro Detroit Endocrinology Center
    • Minnesota
      • Rochester, Minnesota, Spojené státy, 55902
        • Mayo Clinic
    • Mississippi
      • Madison, Mississippi, Spojené státy, 39110
        • Mississippi Center for Advanced Medicine
    • Missouri
      • Chesterfield, Missouri, Spojené státy, 63017
        • St. Luke's Hospital
      • Kansas City, Missouri, Spojené státy, 64108
        • Children's Mercy
      • St Louis, Missouri, Spojené státy, 63130
        • Washington University in St. Louis
    • New York
      • Buffalo, New York, Spojené státy, 14260
        • University of Buffalo
      • New York, New York, Spojené státy, 10032
        • Columbia University
      • New York, New York, Spojené státy, 10029
        • Mount Sinai Hospital
      • New York, New York, Spojené státy, 10029
        • Metropolitan Hospital Center
      • Staten Island, New York, Spojené státy, 10306
        • Ten's Medical Center - Pediatric Endocrinology Clinic
    • Ohio
      • Cincinnati, Ohio, Spojené státy, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Spojené státy, 44195
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, Spojené státy, 97239
        • Oregon Health & Science University
    • Pennsylvania
      • Danville, Pennsylvania, Spojené státy, 17822
        • Geisinger Clinic
      • Philadelphia, Pennsylvania, Spojené státy, 19104
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, Spojené státy, 15213
        • UPMC Montefiore
    • Tennessee
      • Nashville, Tennessee, Spojené státy, 37232
        • Vanderbilt University School of Medicine
    • Texas
      • Amarillo, Texas, Spojené státy, 79106
        • Texas Tech
      • Houston, Texas, Spojené státy, 77030
        • Texas Children's Hospital
      • Houston, Texas, Spojené státy, 77084
        • Biopharma Informatic
      • McAllen, Texas, Spojené státy, 78503
        • Rio Grande Valley Endocrine Center
      • Plano, Texas, Spojené státy, 75093
        • Endocrine Associates of Dallas and Plano
    • Washington
      • Tacoma, Washington, Spojené státy, 98405
        • MultiCare Health System Institute for Research and Innovation
    • West Virginia
      • Morgantown, West Virginia, Spojené státy, 26506
        • West Virginia University
    • Wisconsin
      • Marshfield, Wisconsin, Spojené státy, 54449
        • Marshfield Clinic Research Foundation, a Division of Marshfield Clinic, Inc
      • Rio, Řecko, 26504
        • University of Patras School of Medicine
      • Barcelona, Španělsko, 08950
        • Hospital Sant Joan de Deu, Barcelona
      • Cadiz, Španělsko
        • Puerta del Mar University Hospital
      • Madrid, Španělsko, 28040
        • Hospital Fundación Jimenez Díaz
      • Málaga, Španělsko, 29010
        • Hospital Universitario Virgen de la Victoria de Málaga
      • Valencia, Španělsko, 46014
        • Hospital General de Valencia

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

6 let až 65 let (Dítě, Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Participants must have a pre-identified:

    • Heterozygous genetic variant in the POMC gene or PCSK1 gene
    • Heterozygous genetic variant in the LEPR gene
    • Homozygous, heterozygous, or compound heterozygous variant in the NCOA1 (SRC1)
    • Homozygous, heterozygous, or compound heterozygous variant in SH2B1 gene, or chromosomal 16p11.2 deletion encompassing the SH2B1 gene
  • Between 6 and 65 years of age at the time of provision of informed consent/assent

  • Obesity, defined as body mass index (BMI) ≥30 kg/m^2 for participants ≥18 years of age or BMI ≥95th percentile for age and gender for participants 6 up to 17 years of age

  • Participant and/or parent or guardian is able to understand and comply with the requirements of the study and is able to understand and sign the written informed consent/assent

  • Participant and/or parent or guardian reports that participant experienced childhood obesity, defined as the participant and/or parent or guardian reporting that the participant had obesity or was significantly overweight during childhood

  • Agree to use a highly effective form of contraception throughout the study and for 90 days following the study

  • Reported history of lifestyle intervention of diet and exercise

  • Symptoms or behaviors of hyperphagia persistent during the participant's life, including manifestations in childhood, as determined by the Investigator at screening.

Key Exclusion Criteria:

  • Weight loss of 2% or greater in the previous 3 months
  • Bariatric surgery or procedure within the previous 6 months
  • Significant psychiatric disorder(s)
  • Suicidal ideation, attempt or behavior
  • Clinically significant pulmonary, cardiac, endocrine/metabolic, hepatic or oncologic disease
  • Glycated hemoglobin (HbA1C) >10% at Screening
  • History of significant liver disease or severe kidney disease
  • History or close family history (parents or siblings) of melanoma, or participant history of oculocutaneous albinism
  • Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
  • Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing
  • Previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide
  • Significant hypersensitivity to any excipient in the study drug
  • If female, pregnant or breastfeeding

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Trojnásobný

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: POMC or PCSK1 variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Experimentální: LEPR variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Experimentální: NCOA1 (SRC1) variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Experimentální: SH2B1 variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Treatment Period: Percent Change From Baseline in Body Mass Index (BMI)
Časové okno: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kilograms (kg)/(height in meters [m])^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. An analysis of covariance (ANCOVA) model was used to calculate the least-squares mean with randomization stratification factors and baseline value as a covariate.

Baseline, Week 52

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Treatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMI
Časové okno: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body Weight
Časové okno: Baseline, Week 52

Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration

Baseline, Week 52
Treatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger Score
Časové okno: Baseline, Week 52

Participants ≥12 years of age who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." The 'most hunger' item was designed to be evaluated separately and was averaged on a weekly basis. Participants were asked 'In the last 24 hours, how hungry did you feel when you were the most hungry?' and rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible). Data reported are for mean percent change from baseline in the weekly average daily most hunger score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMI
Časové okno: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-score
Časové okno: Baseline, Week 52

BMI z-scores were calculated according to the Centers for Disease Control and Prevention (CDC) Growth Charts and according to participant's gender and age at screening. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (> 0) indicated an increase in BMI from Baseline. Data reported are for mean percent change from baseline in BMI Z-score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th Percentile
Časové okno: Baseline, Week 52

The percentage change from baseline in BMI 95th percentile was calculated as ([BMI at Week 52 / BMI 95th percentile]) - [BMI at baseline / BMI 95th percentile])*100. BMI percentile scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Data reported are for mean percent change from baseline in BMI 95th percentile. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Baseline, Week 52
Treatment Period: Percent Change From Baseline in Waist Circumference
Časové okno: Baseline, Week 52

The waist circumference (in centimeters [cm]) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Data reported are for mean percent change from baseline in waist circumference. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Časové okno: Baseline up to 60 weeks

TEAEs were defined as any untoward medical occurrence temporally associated with the use of study treatment, whether or not considered related to the study treatment that happened on or after the date of the first study treatment administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Baseline up to 60 weeks
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-Lite
Časové okno: Baseline, Week 52

The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire. The physical function domain comprised 11 items which had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The score of each item was summed to calculate the raw score. The raw score range of the physical function domain was 11-55 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in physical functioning score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy
Časové okno: Baseline, Week 52

The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire. The physical comfort domain comprised 6 items which used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw score. The raw score range of the physical function domain was 6-30 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Lite
Časové okno: Baseline, Week 52

The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire which comprised of 5 domains (physical function, self-esteem, sexual life, distress and work) and had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The items were summed to calculate the raw total score. The raw total score range was 31-155 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy
Časové okno: Baseline, Week 52

The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire and comprised of 4 domains (physical comfort, body esteem, social life, family relations) and used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw total score. The raw total score range was 27 to 135 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus Placebo
Časové okno: Baseline, Week 52

Initial responders were defined as setmelanotide treated participants with ≥5% body weight loss (≥18 years of age) or a decrease in BMI by ≥3% (<18 years of age) at the time of consecutive 12 weeks with the increased 3.0 mg/day or with final increased dose level. Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Studijní židle: David Meeker, MD, Rhythm Pharmaceuticals, Inc.

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

26. dubna 2022

Primární dokončení (Aktuální)

19. prosince 2025

Dokončení studie (Aktuální)

30. června 2026

Termíny zápisu do studia

První předloženo

30. září 2021

První předloženo, které splnilo kritéria kontroly kvality

13. října 2021

První zveřejněno (Aktuální)

26. října 2021

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

12. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

19. října 2026

Naposledy ověřeno

1. října 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • RM-493-035

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

produkt vyrobený a vyvážený z USA

Ano

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .